SCHEMBL18436754

SCHEMBL18436754

Cc1ccc(N2CC(C)N(C(=O)OC(C)(C)C)C(C)C2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.56
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.39
HSD11B1 P28845 1/20 0.38
MET P08581 1/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19001024 0.87 HSD11B1 (0.51) GPR119KMT2AMAPTALDH1A1LMNA
SCHEMBL5726247 0.87 GPR119 (0.43) GPR119KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL24681357 0.87 GPR119 (0.43) GPR119MAPTALDH1A1LMNAHSD11B1
SCHEMBL6073574 0.87 GPR119 (0.43) GPR119KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL21336726 0.87 GPR119 (0.56) GPR119MAPTALDH1A1LMNA
SCHEMBL7661671 0.86 GPR119 (0.58) GPR119KMT2AMEN1SMN1; SMN2CYP2C19
SCHEMBL7661674 0.86 GPR119 (0.58) GPR119KMT2AMEN1SMN1; SMN2CYP2C19
SCHEMBL22048425 0.85 GPR119 (0.59) GPR119KMT2AMEN1SMN1; SMN2CYP2C19
SCHEMBL19012629 0.85 GPR119 (0.41) GPR119KMT2AMEN1SMN1; SMN2CYP2C19
SCHEMBL20469236 0.84 GPR119 (0.59) GPR119KMT2AMEN1SMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124482-B1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) 2019-09-11 EP disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH GPR119 1965/4885KMT2A 325/4885MEN1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.